2.40

9.09% -0.24

After Hours: 2.40

Moleculin Biotech Inc (MBRX)

Overview News Price History Financials Discussions Forecast Stock Split

Moleculin Biotech Inc stock is traded at $2.40, with a volume of 404.63K. It is down -9.09% in the last 24 hours and up +0.00% over the past month. Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Previous Close:

$2.64

Open:

$2.59

24h Volume:

404.63K

Relative Volume:

0.87

Market Cap:

$12.81M

Revenue:

Net Income/Loss:

$-30.33M

P/E Ratio:

-0.0856

EPS:

-28.0369

Net Cash Flow:

$-24.28M

1W Performance:

-32.77%

1M Performance:

+0.00%

6M Performance:

-41.75%

1Y Performance:

-71.76%

1-Day Range:

$2.375

$2.6499

1-Week Range:

$2.35

$3.05

52-Week Range:

$1.79

$24.00

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name

Moleculin Biotech Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

713-300-5160

Address

5300 MEMORIAL DRIVE, HOUSTON, TX

Employee

Twitter

@moleculinbio

Next Earnings Date

2026-08-11

Latest SEC Filings

MBRX's Discussions on Twitter

Compare MBRX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBRX Moleculin Biotech Inc	2.40	14.89M	0	-30.33M	-24.28M	-28.04
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-09-25	Resumed	H.C. Wainwright	Buy
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform

Moleculin Biotech Inc Stock (MBRX) Latest News

Jul 01, 2026

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Jul 01, 2026

What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI

Jul 01, 2026

Jun 30, 2026

Why is Moleculin stock falling today? - MSN

Jun 30, 2026

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance - Asianet Newsable

Jun 30, 2026

Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data. - Bitget

Jun 30, 2026

Moleculin Biotech Updates Investors With New Presentation - TipRanks

Jun 30, 2026

Moleculin Biotech Reports Promising Annamycin AML Trial Data - TipRanks

Jun 30, 2026

Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates - Minichart

Jun 30, 2026

Moleculin reports positive interim data from AML trial By Investing.com - Investing.com Canada

Jun 30, 2026

Form 8-K Moleculin Biotech, Inc. For: Jun 30 - StreetInsider

Jun 30, 2026

Moleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercised - Stock Titan

Jun 30, 2026

Moleculin Reports Positive Phase 2/3 MIRACLE Interim - GlobeNewswire

Jun 30, 2026

Jun 26, 2026

MBRX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Moleculin Biotech, Inc. Actuals & Estimates (MUN:MOL0) - TradingView

Jun 26, 2026

Jun 25, 2026

Moleculin Biotech, Inc. Actuals & Estimates (LSE:0K2H) - TradingView

Jun 25, 2026

0K2H Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Form 4 Moleculin Biotech Inc For: 24 June By Investing.com - Investing.com Nigeria

Jun 25, 2026

Jun 24, 2026

Moleculin Biotech (MBRX) CEO reports RSU vesting, tax-share withholding and retained stake - Stock Titan

Jun 24, 2026

Moleculin Biotech (MBRX) CSO exercises RSUs with tax withholding, increases common stock stake - Stock Titan

Jun 24, 2026

Jun 23, 2026

MBRX Stock Whipsaws As Traders Focus On Cash Runway - StocksToTrade

Jun 23, 2026

SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits

Jun 23, 2026

MBRX Stock Draws Trader Focus As Volatility Spikes - timothysykes.com

Jun 23, 2026

$Moleculin Biotech (MBRX.US)$ - Moomoo

Jun 23, 2026

Trending Stocks Today | Moleculin Biotech Shoots up 106.41% Pre-Market - Moomoo

Jun 23, 2026

Jun 22, 2026